In vitro administration of melatonin resulted in an increase in Clock and Per2 levels and a concurrent decrease in Bma11, effectively “re-synchronizing” the once dysregulated circadian rhythm circuitry seen in the prostate cancer cells. This evidence concerns the gene PER2 and prostate cancer.